DelveInsight’s Diabetic Retinopathy Market Insights report offers detailed information on current treatment practices, emerging drugs, Diabetic Retinopathy market share of the individual therapies, current and forecasted Diabetic Retinopathy market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

 

Some of the key takeaways from the Diabetic Retinopathy Market Insights: 

• The total diagnosed Diabetic Retinopathy prevalent population in the 7MM countries was estimated to be 8,033,083 cases in 2020.
• The United States accounted for the highest percentage of Diabetic Retinopathy prevalent in the population. 
• Anti-vascular endothelial growth factor (anti-VEGF) drugs including Aflibercept (Eylea from Regeneron and Bayer), Ranibizumab (Lucentis from Genentech and Novartis), and Bevacizumab (Avastin from Genentech) are considered the first line of therapy for the treatment. 
• Currently, Aflibercept is the accepted standard of care and the market-leading drug in virtually all retinal disorders. Interestingly, Bevacizumab is used off label in ocular indications but is widely reimbursed. 
• The reasons for choosing one anti-VEGF over another are multifactorial and include retinal thickness, disease progression, best-corrected visual acuity (BCVA), reimbursement, and patient and family influences.
• Among the 7MM, the US accounted for 57.0% of the overall Diabetic Retinopathy market size in 2020.
• The Diabetic Retinopathy market has a lot of opportunities for biosimilars and novel biochemical pathways. 
• Novartis Pharmaceuticals (Brolucizumabt), Roche (Faricimab), Adverum Biotechnologies (ADVM-022), Kubota Vision (Emixustat Hydrochloride), KalVista Pharmaceuticals (KVD001), Kodiak Sciences (KSI-301), and others. 
• However, the expected patents expiries of Aflibercept (in 2022) and Ranibizumab (in 2023), along with the potential launch of biosimilars is expected to dilute the market share of these drugs. 
• The expected launch of pipeline therapies such as Faricimab, Brolucizumab, Emixustat Hydrochloride, ADVM-022, and KSI-301 during the forecast period (2021–2030) shall create a lot of buzz in the market and push the market size growth further. 
• Phase II assets include ADVM-022, Emixustat Hydrochloride, along with Risuteganib.
• Owing to rising awareness and understanding of the disease, favourable conditions for novel anti-infective modalities are expected to lead more pharma companies to set their feet in the Diabetic Retinopathy therapy market, thus, expanding the market size.

 

Download report to know which drug is going to capture the maximum market share @ Diabetic Retinopathy Market Analysis and Forecast

 

Diabetic Retinopathy: Disease Overview 

Diabetic Retinopathy is a significant complication of diabetes mellitus, which is a leading cause of visual loss in working-age populations. With an increasing prevalence of diabetes, it appears that the prevalence of Diabetic Retinopathy is also on the rise. Type 2 diabetes, which is becoming more common, leads to over 60% of patients diagnosing with Diabetic Retinopathy within the first 20 years of onset. 

Furthermore, Age is a noteworthy risk factor for Diabetic Retinopathy prevalence as the chances increase with the age. 

 

For a comprehensive analysis, visit Diabetic Retinopathy Epidemiological Analysis and Changing Trends 

 

Diabetic Retinopathy Epidemiology Segmentation

Diabetic Retinopathy Market and Epidemiology Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:

• Total Diagnosed Diabetic Retinopathy Prevalent Cases 
• Gender-Specific Diabetic Retinopathy Cases
• Age-Specific Diabetic Retinopathy Cases
• Severity-Specific  Diabetic Retinopathy Cases

The report proffers a holistic view of the present Diabetic Retinopathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs that help clients curate the best of the opportunities and assess the market’s hidden potential, and plans strategically to handle market risks.

 

Diabetic Retinopathy Therapy Market

The present scenario in the Diabetic Retinopathy therapeutic landscape appears quite confined, limited to laser treatment, eye injections, and anti-VEGF drugs, which are the preferred first line of therapy. The treatments for DR relies heavily on the presence of macular edema.

Available anti-VEGF drugs include aflibercept (Eylea from Regeneron and Bayer), ranibizumab (Lucentis from Genentech and Novartis), and bevacizumab (Avastin from Genentech) that are presently enjoying the monopoly in the Diabetic Retinopathy market.

However, there exist several gaps in the Diabetic Retinopathy therapeutic market in the form of an absence of biomarkers, a lack of technologies that are potential enough to predict the disease course in patients, and novel pathways to offer novel treatments. 

 

Reach out to us @ Diabetic Retinopathy Marketed Therapies for more information on available treatment regimens 

 

Diabetic Retinopathy Market 

The Diabetic Retinopathy market encompasses several novel pipeline therapies with better efficiency and tolerability than conventional and available therapies. Key companies such as Novartis, Roche, Kodiak Sciences, Adverum Biotechnologies, Kubota Vision, Allegro Ophthalmics, and several others are developing new drugs that project a promising picture of the Diabetic Retinopathy market landscape in the coming decade. 

The market has limited options to offer, and a lack of gene therapy, personalized treatment approaches offer pharma companies a latitude to explore and penetrate with novel gene therapies, biosimilars into the market. 

This does not only promise one-time treatment but also facilitates the usage of lower doses ascribed to favorable anatomy of the eye owing to its size. Moreover, an increasing patient pool also gives pharma companies room for making cost-effective drugs without compromising with gains. Different possible pathways have been extensively studied, which could be responsible for the disease. Therefore, a better understanding has been obtained through years of thorough research and development. The emergence of personalized medications is expected to further drive the growth of the DR market share. 

 

Diabetic Retinopathy Pipeline Therapies and Key Companies

Brolucizumabt: Novartis Pharmaceuticals  Faricimab: Roche  ADVM-022: Adverum Biotechnologies Emixustat Hydrochloride: Kubota Vision  KVD001: KalVista Pharmaceuticals

 

Get a detailed analysis of Diabetic Retinopathy Emerging Drug Pipeline and Key Companies 

 

Scope of the Report 

Coverage: 7MM (the US, EU5, and Japan) Study Period: 2019-32 Key Companies: Novartis, Roche, Adverum Biotechnologies, Kubota Vision, Kodiak Sciences andAllegro Ophthalmics. Key Diabetic Retinopathy Pipeline Therapies: Brolucizumab, Faricimab, ADVM-022, Emixustat Hydrochloride, KVD001, KSI-301 and Risuteganib. Diabetic Retinopathy Market Segmentation: By Geography, By Diabetic Retinopathy Therapies Analysis: Comparative and conjoint analysis of Diabetic Retinopathy emerging therapies Tools used: SWOT analysis, Conjoint Analysis, Porter’s Five Forces, PESTLE analysis, BCG Matrix analysis methods. Case Studies KOL’s Views Analyst’s Views

 

Table of Contents 

1	Key Insights
2	Diabetic Retinopathy Market Report Introduction
3	Diabetic Retinopathy Market Overview at a Glance
4	Executive Summary of Diabetic Retinopathy
5	Disease Background and Overview
6	Organizations in the Diabetic Retinopathy Market
7	Diabetic Retinopathy Epidemiology and Patient Population
8	Diabetic Retinopathy Treatment
9	Diabetic Retinopathy Marketed Therapies
10	Diabetic Retinopathy Emerging Therapies
11	Diabetic Retinopathy: 7 Major Market Analysis
10	The United States Diabetic Retinopathy Market Analysis
12	EU5 Diabetic Retinopathy Market Analysis
13	Japan Diabetic Retinopathy Market Analysis
14	Diabetic Retinopathy Market Unmet Needs
15	Case Reports
16	Diabetic Retinopathy Market Drivers
17	Diabetic Retinopathy Market Barriers
18	SWOT Analysis
19	KOL Reviews
20	Appendix
21	DelveInsight Capabilities
21	Disclaimer

 

About DelveInsight

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/diabetic-retinopathy-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr